XML 64 R9.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenue | 3 Months Ended
--- | ---
Dec. 31, 2019
Revenue From Contract With Customer [Abstract] |
Revenue | 2. Revenue The following table presents our revenues disaggregated by product classification and by operating segment, excluding sales taxes collected and remitted to governmental authorities (in thousands, unaudited).
|  | Three Months Ended |
|  | December 31, |
(Dollars in thousands) |  | 2019 |  |  | 2018 |
Medical Device |  |  |
Product sales |  | $ | 5,023 |  |  | $ | 4,778 |
Royalties |  |  | 8,898 |  |  |  | 7,685 |
Research, development and other |  |  | 2,234 |  |  |  | 2,384 |
License fees |  |  | 1,249 |  |  |  | 2,411 |
Total Revenue - Medical Device |  |  | 17,404 |  |  |  | 17,258 |
IVD |  |  |  |  |  |  |  |
Product sales |  |  | 4,952 |  |  |  | 4,973 |
Other |  |  | 260 |  |  |  | 10 |
Total Revenue - IVD |  |  | 5,212 |  |  |  | 4,983 |
Total Revenue |  | $ | 22,616 |  |  | $ | 22,241 |
Contract Assets, Deferred Revenue and Remaining Performance Obligations Contract asset balances consist of estimated sales-based royalties earned but not collected at each balance sheet date and are subject to timing fluctuations at the end of a given period. The Company’s deferred revenue, or contract liability, is primarily related to the upfront and milestone payments received pursuant to the collaborative license and commercialization agreement with Abbott (the “Abbott Agreement”) for the Company’s SurVeil™ drug-coated balloon product (“SurVeil DCB”) discussed in Note 3. As of December 31, 2019, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more totaled approximately $15.8 million. These remaining performance obligations relate to the Abbott Agreement (Note 3), exclude contingent milestone payments under the Abbott Agreement, and are expected to be recognized over the next six years as services, principally the TRANSCEND study, are completed.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration